BioPorto
Update in progressBIOPOR.CO (Copenhagen)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDiagnostics & Research
BioPorto A/S is an in vitro diagnostics company that develops biomarker tests to help clinicians detect kidney injury earlier in critically ill patients. Based in Hellerup, Denmark, it serves Europe, North America and Asia. Its offerings include ProNephro AKI (NGAL) for pediatric AKI, the NGAL Test for quantifying NGAL in urine and blood, antibodies for diagnostic immunoassays, ready-to-use NGAL ELISA kits, and the generic Rapid Assay Device (gRAD) for custom lateral flow assays. Founded 1917.
Company score
- Sentiment
- 0.49
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.49
- Governance
- 0.15
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.18
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.34
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketCopenhagen (CPH)
- LocationDenmark
- CEOMr. Jeffrey N. Haas
- Founded1917
- Employees44
- Websitebioporto.com
Identifiers
- ISINDK0011048619